Dissemin is shutting down on January 1st, 2025

Published in

Wiley, Mycoses, 12(64), p. 1508-1511, 2021

DOI: 10.1111/myc.13373

Links

Tools

Export citation

Search in Google Scholar

Interaction between flucloxacillin and azoles: Is isavuconazole next?

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractBackgroundIsavuconazole is a triazole antifungal drug, approved for the treatment of invasive aspergillosis and mucormycosis. It has been previously reported that an interaction between flucloxacillin and voriconazole may lead to subtherapeutic voriconazole exposure, when used concomitantly. Since isavuconazole is also metabolised via cytochrome P450 enzymes, the same interaction may be expected.ObjectivesWe aim to document exposure to isavuconazole in patients concomitantly treated with flucloxacillin.PatientsWe report two patients treated with both isavuconazole and flucloxacillin, in whom we determined isavuconazole concentrations.ResultsLow isavuconazole trough concentrations (<1 mg/L) were observed in two patients under concomitant treatment with flucloxacillin.ConclusionsIn combination with flucloxacillin, low isavuconazole concentrations were observed but an adequate isavuconazole exposure may be reached with dose augmentation. Therapeutic drug monitoring of isavuconazole is recommended to ensure an adequate exposure.